Clinical Investigation in Tumor Immunotherapy

描述（由申请人提供）：此K24职业发展奖将 请允许我继续我的努力，“翻译”肿瘤免疫学从 实验室进入临床，以改善成人实体瘤的治疗。 这些 努力将基于免疫的治疗应用于泌尿生殖系统癌症 （尤其是前列腺）和黑色素瘤。 审判将基于强大的 科学原理，需要与实验室科学家合作， 需要适当的患者基础，并将实验室和 免疫学终点以及标准临床终点。 的 临床研究计划将针对三个主要目标： 1.开发和测试前列腺癌的免疫方法; 2.继续研究黑色素瘤生物学，开发新的治疗方法 这种疾病。 待测试的疗法可能不仅仅是基于免疫的 办法，并将包括各级（机构， 多机构和大型合作组）的试验设计， 执行; 3。继续努力使细胞因子工作组 (CWG)一个NCI资助的肿瘤免疫治疗合作小组， 快速和创造性地测试更复杂的免疫导向机制 主要用于II期临床试验。 临床初期的指导 调查人员是K24的关键组成部分，将重点关注 将初级教员和/或血液学/肿瘤学研究员带入几个 具有明确职责和教育计划的培训领域。 这些措施包括：1.肿瘤免疫治疗计划强调临床前， 实验室工作，将免疫监测纳入临床试验 设计、方案编制和实施; 2.泌尿生殖系统（GU） 癌症多学科计划，重点是前列腺免疫治疗; 和3.作为临床研究部的主任， 血液学/肿瘤学介绍临床试验研究 包括教师专业知识的概述以及如何启动临床 和一个教员一起调查 此外，我将作为一个 临床研究的顾问。 通过联合我的努力 实验室工作和免疫学终点以及强有力的临床试验 设计，相信临床研究可以更好地推动肿瘤免疫治疗 以更理性的方式前进。

DESCRIPTION (provided by applicant): This K24 Career Development Award will allow me to continue my efforts to "translate" tumor immunology from the laboratory into the clinic to improve therapy of adult solid tumors. These efforts will apply immune-based treatments to genitourinary cancers (especially prostate) and melanoma. The trials will be based on strong scientific rationale, require collaborations with laboratory scientists, require an appropriate patient base, and incorporate laboratory and immunologic endpoints in addition to standard clinical endpoints. The clinical research program will be directed towards three major objectives: 1. developing and testing immunotherapeutic approaches for Prostate Cancer; 2. continue to study Melanoma biology and develop novel therapeutic approaches to this disease. Therapies to be tested may extend beyond solely immune-based approaches and will include active participation at all levels (institutional, multi-institutional, and large cooperative group) of trial design and implementation; and 3. continue efforts to make the Cytokine Working Group (CWG) an NCI funded cooperative group in Tumor Immunotherapy by becoming a mechanism to rapidly and creatively test more complex immune oriented approaches primarily in phase II trials. The mentoring of beginning clinical investigators is a critical component of the K24 and will be focused on bringing junior faculty and/or Hematology/Oncology fellows into one of several areas of training with well defined responsibilities and educational programs. These include: 1. the Tumor Immunotherapy Program emphasizing pre-clinical, laboratory work, incorporation of immune monitoring into clinical trial design, and protocol preparation and implementation; 2. Genitourinary (GU) Cancer Multidisciplinary Program with an emphasis on prostate immunotherapy; and 3. As the Director of Clinical Research within the Section of Hematology/Oncology provide an introduction to clinical trials research including an overview of faculty expertise and how to initiate clinical investigation with one of the faculty. Furthermore, I will act as a consultant for their clinical research. By combining my efforts to merge laboratory efforts and immunologic endpoints with strong clinical trial design, I believe clinical research can better move tumor immunotherapy forward in a more rationale way.